Pharmacokinetics, Safety and Tolerability of Anacetrapib, a Novel Cholesteryl Ester Transfer Protein (CETP) Inhibitor, After Single and Multiple Doses in Healthy Chinese Subjects-Reference-Cited by-同舟云学术

Pharmacokinetics, Safety and Tolerability of Anacetrapib, a Novel Cholesteryl Ester Transfer Protein (CETP) Inhibitor, After Single and Multiple Doses in Healthy Chinese Subjects

Published:2021-06-08 Issue:7 Volume:38 Page:3973-3985
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Chen Hanjing^ORCID,Chen Weili,Li Hui,Xu Hongrong,Yuan Fei,Sheng Lei,Liu Chao,Lin Pingping,Yang Mengjie,Li Xuening^ORCID,Liu Yang,Walker Brittany Marie,Gheyas Ferdous,Iwamoto Marian,Stoch S. Aubrey,Krishna Rajesh

Funder

MSD China

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12325-021-01794-8.pdf

Reference27 articles.

1. Krishna R, Anderson MS, Bergman AJ, Jin B, Fallon M, Cote J, et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet (London, England). 2007;370(9603):1907–14.

2. Group HTRC, Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, et al. Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med. 2017;377(13):1217–27.

3. Merck Provides Update on Anacetrapib Development Program [Internet]. Available from: https://investors.merck.com/news/press-release-details/2017/Merck-Provides-Update-on-Anacetrapib-Development-Program/default.aspx. Accessed 4 Jul 2019

4. Rashid S. Lower LDL is better—can this be achieved with CETP inhibition therapy? Expert Rev Cardiovasc Ther. 2020;18(1):1–5.

5. Tardif JC, Rheaume E, Lemieux Perreault LP, Gregoire JC, Feroz Zada Y, Asselin G, et al. Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib. Circ Cardiovasc Genet. 2015;8(2):372–82.